Filter Results:
(125)
Show Results For
- All HBS Web
(125)
- People (1)
- News (41)
- Research (70)
- Multimedia (1)
- Faculty Publications (15)
Show Results For
- All HBS Web
(125)
- People (1)
- News (41)
- Research (70)
- Multimedia (1)
- Faculty Publications (15)
- 09 Aug 2016
- First Look
August 9, 2016
spending in the United States, accounting for less than 1% of prescriptions filled but nearly 28% of drug spending. Whereas traditional (chemically synthesized, "small-molecule") View Details
Keywords: Sean Silverthorne
- 01 Jun 2000
- News
The Business of Biotech
biotechnology. The prospect is exhilarating, but the road to this brave new biotech world has more than a few bumps. With an average time line of ten years required to bring a drug to market - and the potential for failure looming every... View Details
Keywords: Julia Hanna
- 06 Dec 2021
- News
Vision: Sound Science
of scientific inquiry in gene-based hearing loss and inner-ear drug delivery: “In some infants with profound hearing impairment, there’s a mutation in one of those genes that results in loss of a protein that inner-ear cells need to... View Details
Keywords: Deb Blagg
- 07 Aug 2000
- Research & Ideas
The Business of Biotech
coming of age of biotechnology. The disappearance of "blockbuster" drugs could create new management challenges for pharmaceutical companies. — Gary Pisano The prospect is exhilarating, but the road to this brave new biotech... View Details
- 30 May 2007
- Research & Ideas
Health Care Under a Research Microscope
Cambridge, Massachusetts, and you will likely be administered beta blockers, a class of drug that's generally recommended after a heart attack. The rate at which that drug is delivered nationwide, however,... View Details
- 01 Mar 2007
- News
HBS Alums Help Jailhouse Entrepreneurs Go Straight
Like it or not, a drug dealer, for example, already knows a lot about what it takes to run a successful business. Teaching them passion is not something we have to do; what we teach them is how to go legit.” At HBS, several students are... View Details
- 27 Jun 2005
- Research & Ideas
The Potential Downside of Win-Win
consideration for all managers. Value Creation—and Collusion Suppose that pharmaceutical firm A manufactures a new, beneficial drug and begins selling 100 million pills per year at $3.05 per pill. Each pill costs 5 cents to manufacture,... View Details
Keywords: by Max H. Bazerman
- 01 Sep 2006
- News
Sorry, We’re All Out of Chilean Sea Bass
places our food comes from and us the consumers. And that’s part of the problem. Do you think it was worth spending millions of taxpayer dollars and endangering lives to pursue the fishing vessel? The economic incentives for this kind of... View Details
- Profile
Henry McCance
a few FDA-approved drugs for Alzheimer’s disease, and they won’t help,’” he recalls. McCance, a venture- capital pioneer with Greylock Partners, had spent 40 years as eyewitness to advances in technology that changed the world at... View Details
- 07 Oct 2014
- News
Network Effect
was shocked by their advice. “They said, ‘Try three Advil a day. It might help. There are a few FDA-approved drugs for Alzheimer’s disease, and they won’t help,’” he recalls. McCance, a venture- capital pioneer with Greylock Partners, had... View Details
Keywords: Linda Kush
- 13 Oct 2016
- News
Adding Muscle to the Fight Against Disease
biotech companies—as a function of cost, time, and failure modes—tend to risk pivot on one program, one clinical trial, one outcome,” he observes. “Our company is the leader in mining muscle biology for drug discoveries that translate... View Details
Keywords: Deborah Blagg
- 05 May 2020
- News
“Walking a Tightrope”
Kristof, most of which have focused on poverty in developing countries. But in the Pulitzer Prize-winning duo’s latest book, Tightrope: Americans Reaching for Hope, they turn their lens on working class communities in the United States—communities that have been... View Details
- 01 Jun 2001
- News
Stephen M. Moret: A Campaign for Positive Change
low-cost HIV/AIDS drugs to Malawi. “I’m the guy who still can’t believe I got to go to school here.” After traveling around the world this fall, Moret will take a position in McKinsey’s Washington, D.C., office, where he hopes to View Details
- 15 Dec 2014
- Research & Ideas
Deconstructing the Price Tag
itemizes what it spends on cotton, cutting, sewing, dyeing, finishing, and transporting each shirt, consumers become more attracted to the brand and more likely to purchase. “By unpacking the costs, you have the opportunity to explain... View Details
- 12 Jan 2016
- First Look
January 12, 2016
November–December 2015 Operations Research Active Postmarketing Drug Surveillance for Multiple Adverse Events By: Goh, Joel, Margrét V. Bjarnadóttir, Mohsen Bayati, and Stefanos A. Zenios Abstract—Postmarketing View Details
Keywords: Carmen Nobel
- 20 May 2016
- Op-Ed
World Health Organization Lacks Leadership to Combat Pandemics
greater role in WHO governance and if there are guarantees of purchase contracts for new drugs and vaccines at sensible prices. Both seem unlikely, as the WHO's culture has always winced at cooperation with the private sector. WHO's track... View Details
- 28 Jul 2009
- First Look
First Look: July 28
they cannot spend on marketing the way their competitors do. The case invites students to explore an unusual business model in both concept and execution. Purchase this case: http://cb.hbsp.harvard.edu/cb/product/609106-PDF-ENG Pfizer:... View Details
Keywords: Martha Lagace
- 01 Dec 2009
- News
Seven Honored with Alumni Achievement Award
Merck, Gillette, and Searle, Kathy Giusti was diagnosed in 1996 with multiple myeloma, a rare and incurable blood cancer. She then founded the Multiple Myeloma Research Foundation and the Multiple Myeloma Research Consortium, organizations that have revolutionized... View Details
- 14 Apr 2021
- Research & Ideas
The High Cost of the Slow COVID Vaccine Rollout
the United States, the Federal Drug Administration this week advised states to pause the use of the Johnson & Johnson vaccine after six women developed a rare blood-clotting disorder, raising new concerns about total vaccine supply.... View Details
- 24 Sep 2020
- News
The Race for a Vaccine
Pisano says. But vaccines don’t really fit the same business model as high-volume therapeutic drugs; they have an even higher bar for safety and effectiveness, because unlike most other drugs they are administered to healthy populations.... View Details